Daisuke Kato, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Red-Cell Aplasia, Pure | 1 | 2019 | 30 | 0.690 |
Why?
|
| Erythema Infectiosum | 1 | 2019 | 15 | 0.690 |
Why?
|
| Parvoviridae Infections | 1 | 2019 | 35 | 0.690 |
Why?
|
| Parvovirus B19, Human | 1 | 2019 | 38 | 0.690 |
Why?
|
| Muscarinic Antagonists | 1 | 2017 | 137 | 0.580 |
Why?
|
| Acetanilides | 1 | 2017 | 168 | 0.550 |
Why?
|
| Urinary Bladder, Overactive | 1 | 2017 | 106 | 0.540 |
Why?
|
| Vinblastine | 2 | 2010 | 490 | 0.410 |
Why?
|
| Thiazoles | 1 | 2017 | 1484 | 0.360 |
Why?
|
| Lymphocytes | 1 | 2017 | 2614 | 0.340 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2017 | 1377 | 0.330 |
Why?
|
| Monocytes | 1 | 2017 | 2593 | 0.310 |
Why?
|
| Medication Adherence | 1 | 2017 | 2055 | 0.270 |
Why?
|
| Antigens, Viral | 3 | 2022 | 1034 | 0.220 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2019 | 5425 | 0.210 |
Why?
|
| Japan | 4 | 2021 | 1360 | 0.200 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 128 | 0.190 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6534 | 0.140 |
Why?
|
| Trypsinogen | 1 | 2015 | 86 | 0.130 |
Why?
|
| Earthquakes | 1 | 2017 | 179 | 0.120 |
Why?
|
| Ethers, Cyclic | 1 | 2014 | 33 | 0.120 |
Why?
|
| Stereoisomerism | 3 | 2010 | 625 | 0.120 |
Why?
|
| Pancreatic Fistula | 1 | 2015 | 145 | 0.120 |
Why?
|
| Leukocyte Count | 1 | 2017 | 1583 | 0.110 |
Why?
|
| Biological Products | 2 | 2014 | 856 | 0.110 |
Why?
|
| Macrolides | 1 | 2014 | 201 | 0.110 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2020 | 987 | 0.110 |
Why?
|
| DNA, Viral | 1 | 2019 | 2224 | 0.110 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2015 | 503 | 0.100 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 1237 | 0.100 |
Why?
|
| Pseudomonas Infections | 1 | 2015 | 608 | 0.090 |
Why?
|
| Oxadiazoles | 1 | 2010 | 93 | 0.090 |
Why?
|
| Transplantation Conditioning | 2 | 2009 | 1597 | 0.090 |
Why?
|
| Communicable Diseases | 1 | 2017 | 878 | 0.080 |
Why?
|
| Histocompatibility Testing | 1 | 2009 | 742 | 0.070 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2015 | 1210 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2022 | 3123 | 0.070 |
Why?
|
| Substrate Specificity | 1 | 2010 | 1802 | 0.070 |
Why?
|
| Amino Alcohols | 1 | 2005 | 16 | 0.070 |
Why?
|
| Cord Blood Stem Cell Transplantation | 2 | 2005 | 314 | 0.070 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 1538 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2022 | 4229 | 0.060 |
Why?
|
| Diamines | 1 | 2005 | 59 | 0.060 |
Why?
|
| Adult | 10 | 2021 | 213712 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 2400 | 0.060 |
Why?
|
| Retrospective Studies | 8 | 2020 | 77098 | 0.060 |
Why?
|
| Ketones | 1 | 2005 | 189 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 9185 | 0.060 |
Why?
|
| Middle Aged | 11 | 2022 | 213127 | 0.050 |
Why?
|
| Fetal Blood | 1 | 2009 | 1317 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 5163 | 0.050 |
Why?
|
| Vascular Neoplasms | 1 | 2004 | 175 | 0.050 |
Why?
|
| Amides | 1 | 2005 | 458 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 14720 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 473 | 0.050 |
Why?
|
| Glycine | 1 | 2005 | 671 | 0.050 |
Why?
|
| Graft vs Host Disease | 3 | 2009 | 2951 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 57683 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2004 | 518 | 0.040 |
Why?
|
| Nasopharynx | 1 | 2022 | 379 | 0.040 |
Why?
|
| Amino Acids | 1 | 2005 | 1727 | 0.040 |
Why?
|
| Young Adult | 4 | 2021 | 56350 | 0.040 |
Why?
|
| Prognosis | 2 | 2017 | 29010 | 0.040 |
Why?
|
| Catalysis | 2 | 2014 | 760 | 0.040 |
Why?
|
| Bacteremia | 1 | 2005 | 962 | 0.040 |
Why?
|
| Female | 11 | 2022 | 379592 | 0.040 |
Why?
|
| Humans | 14 | 2022 | 742088 | 0.040 |
Why?
|
| Aged | 8 | 2021 | 162944 | 0.040 |
Why?
|
| Male | 10 | 2021 | 349538 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2004 | 930 | 0.040 |
Why?
|
| Incidence | 4 | 2020 | 20928 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 11472 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2022 | 1049 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2022 | 1171 | 0.030 |
Why?
|
| Porifera | 1 | 2014 | 33 | 0.030 |
Why?
|
| Hematologic Diseases | 2 | 2005 | 498 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2015 | 3701 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2014 | 2187 | 0.020 |
Why?
|
| Adolescent | 4 | 2021 | 85649 | 0.020 |
Why?
|
| Alkylation | 1 | 2005 | 86 | 0.020 |
Why?
|
| Limbic Encephalitis | 1 | 2004 | 34 | 0.020 |
Why?
|
| Brain Diseases, Metabolic | 1 | 2004 | 42 | 0.020 |
Why?
|
| Clinical Enzyme Tests | 1 | 2004 | 115 | 0.020 |
Why?
|
| Acid Phosphatase | 1 | 2004 | 141 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2009 | 10248 | 0.010 |
Why?
|
| HLA Antigens | 1 | 2009 | 1382 | 0.010 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 272 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2004 | 784 | 0.010 |
Why?
|
| Risk Factors | 3 | 2020 | 72145 | 0.010 |
Why?
|
| Benzhydryl Compounds | 1 | 2005 | 840 | 0.010 |
Why?
|
| Graft Survival | 1 | 2009 | 3733 | 0.010 |
Why?
|
| Hematologic Neoplasms | 1 | 2009 | 1820 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 2004 | 1499 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2017 | 25575 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2021 | 53187 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2004 | 2763 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 35070 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2017 | 40955 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 39004 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 12242 | 0.010 |
Why?
|
| Child | 1 | 2017 | 77478 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2004 | 21719 | 0.000 |
Why?
|
| Animals | 1 | 2014 | 168561 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 13655 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2004 | 62966 | 0.000 |
Why?
|
| Neoplasms | 1 | 2005 | 21596 | 0.000 |
Why?
|